Treatment with anti-CD47 mAb improved renal failure (serum creatinine: anti-CD47 mAb, 0.96 ± 0.30 mg/dL, versus CT-Ab, 0.61 ± 0.32 mg/dL; P <0.05) and attenuated kidney injury in histopathological examination (glomerular score: anti-CD47 mAb, 2.0 ± 0.63, versus CT-Ab, 2.8 ± 0.41; P <0.05) (Figure 4A). This evidence concerns the gene CD47 and Renal insufficiency.